Rhumbline Advisers Achilles Therapeutics PLC Transaction History
Rhumbline Advisers
- $104 Billion
- Q1 2025
A detailed history of Rhumbline Advisers transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Rhumbline Advisers holds 4,480 shares of ACHL stock, worth $6,630. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,480
Previous 4,480
-0.0%
Holding current value
$6,630
Previous $5,000
20.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ACHL
# of Institutions
9Shares Held
5.55MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN3.8MShares$5.63 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA192KShares$283,9060.0% of portfolio
-
Xtx Topco LTD London, X038.9KShares$57,6060.0% of portfolio
-
Brave Asset Management Inc10KShares$14,8000.0% of portfolio
-
Endurance Wealth Management, Inc.2KShares$2,9600.0% of portfolio
About Achilles Therapeutics plc
- Ticker ACHL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,774,000
- Market Cap $60.3M
- Description
- Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...